|Mr. Rick Pauls M.B.A., MBA||Pres, CEO & Director||492.4k||N/A||1971|
|Mr. Scott B. Kellen C.A.||CFO & Company Sec.||280.96k||N/A||1965|
|Dr. Todd A. Verdoorn||Chief Scientific Officer||266.53k||N/A||1962|
|Mr. Edward B. Rady||Chief Commercial Advisor||N/A||N/A||1949|
|Dr. Dennis D. Kim M.B.A., M.D., MBA||Consulting Chief Medical Officer||N/A||N/A||1970|
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company is also developing DM199 for the treatment vascular dementia; and DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.